Introduction
Patients aged 70 and over form a large proportion of those with severe aortic stenosis.' The mortality associated with elective aortic valve replacement in this age group is roughly 5%,2 3 but that associated with emergency operation may be as high as 31%. 3 Valve replacement may not be undertaken in some elderly patients (those considered to have an unacceptably high operative risk or limited life expectancy because of accompanying non-cardiac disease), but data on this have not been included in reports of surgical series.
The use of percutaneous balloon dilatation of the aortic valve to treat calcific aortic stenosis has attracted wide interest since the first report of the technique in 1986. 4 Although it improves valve function and symptoms in the short term,'-its long term efficacy remains unclear. We report on 32 patients who were followed up for up to two years.
Patients and methods
Patients were selected for balloon dilatation of the aortic valve if calcific aortic stenosis had been confirmed by cross sectional echocardiography, Doppler ultrasound, and measurements of intracardiac pressure; they had symptoms of angina, breathlessness, or syncope (New York Heart Association's functional classes II-IV"); appreciable aortic regurgitation (no more than grade 2+ on supravalvar aortography) and left main stem coronary artery disease were absent; and one or more major contraindications to valve replacement had been agreed with a cardiac surgeon. Contraindications included advanced age and infirmity, malignancy, or other non-cardiac disease associated with an increased operative risk. One patient (a 73 year old man) had refused valve replacement.
Coronary arteriography was performed by Judkins's technique through the right femoral artery,'2 followed by supravalvar aortography to assess the degree of aortic regurgitation and identify the orientation of the valve orifice. If the aortic valve was suitable for balloon dilatation the patient was given heparin 5000 units, the right femoral artery was progressively dilated, and a 14 French gauge sheath with a haemostatic valve was inserted. The catheter balloon was introduced by an exchange guide wire (the end of which had been bent into a large J to reduce the risk of perforating the ventricle) and positioned across the aortic valve.
Before the balloon was inflated atropine 1 mg was given intravenously. The balloon was inflated by hand with a mixture of saline and contrast to the manufacturer's maximum recommended pressure (400-600 kPa (4-6 atmospheres)). Inflation was maintained for 10-15 seconds and aortic pressure monitored continuously. Although other workers have used longer periods of inflation,6 7we found that inflation for longer than 15 seconds often resulted in a substantial fall in aortic pressure, which required an infusion of dopamine. Usually several balloons of increasing diameter were used and each inflated two or three times. Cinefilm was taken to confirm full inflation of the balloon and loss of indentation by the stenotic valve.
After each inflation and at the end of the procedure, when the patient's haemodynamic state was stable, simultaneous left ventricular and aortic pressures were recorded. Aortography was not routinely repeated. The arterial sheath was removed, and haemostasis was achieved by pressure.
In one patient (a 70 year old woman with diabetes and peripheral arterial disease) dilatation was performed by a trans-septal approach through the right femoral vein.
Patients were admitted to the coronary care unit for 13 The area of the aortic valve was calculated by a modification of the continuity equation (area of aortic valve=subaortic areaxpeak subaortic velocity/peak aortic velocity); this method has been validated against measurement of the area of the valve by the Gorlin formula.' '7 To measure the subaortic velocity the sample volume was placed in the left ventricular outflow tract in both the apical long axis view and the apical four chamber view, and the maximum velocity was taken. Subaortic area was calculated from the subaortic diameter just below the aortic valve (from the leading edge ofthe left septal border to the leading edge of the anterior mitral leaflet) on freeze frame images recorded in the parasternal long axis view in early systole (subaortic area=(diameter/2)2xn). Echocardiography was performed before the valve was dilated and again before the patient was discharged. When possible further studies were made at intervals of three months during follow up. Echocardiographic and Doppler measurements were made from prints by one observer (DCS).
Patients were questioned about their symptoms and effort tolerance before and one month after operation. 
In several patients the balloon had been seen to oscillate to and fro in the ventricle during inflation before it locked in the valve; presumably this movement drove the tip of the guide wire through the wall of the ventricle. In all cases tamponade was successfully treated by pericardiocentesis. One patient (a 73 year old woman who was in cardiogenic shock before dilatation) died four hours after the procedure after cardiac arrest; echocardiography had not shown recurrence of tamponade. The two other patients made uncomplicated recoveries.
Dissection of the femoral artery occurred in an 83 year old woman who presented in cardiogenic shock; because of the urgency the standard protocol of progressive dilatation of the femoral artery was not followed. Though the dissection was successfully repaired at operation, she remained in low output heart failure and died four days later.
Two patients developed haematomas in the groin but did not require operation. No patient sustained a stroke, and no embolisms were seen. 18 patients and increased from 0-61 (0 16) cm2 to 0 74 (0 23) cm2 (p<0-001) (figure 1). Dilatation had a variable effect on the area. In six patients the area changed by --10% and in 12 patients it increased by 16-56%, becoming >07 cm2 in 11 patients but >10 cm2 in only two. In 11 of 18 patients the area of the valve was measured again six to 50 (mean 23) weeks after dilatation (table IV; (0-21) cm2 before discharge but fell to 0-63 (0 -14) cm2 at follow up. In seven patients the area was less than before dilatation. The mean area at follow up did not differ significantly from that before dilatation (p=0 6). Among the 29 patients alive one month after the procedure symptoms had improved in 17, were unchanged in 11, and were worse in one. Four patients in whom the area of the valve changed by £10% reported an improvement in symptoms. Among the 12 patients in whom the area of the valve increased, symptoms were improved in six, unchanged in five, and worse in one.
Symptoms recurred or worsened in most patients during follow up, and the mortality of the group was high. On 31 January 1988, 16 patients were alive; the mean duration of follow up was 10 months (range 3-24). Two patients had had the aortic valve replaced and four were awaiting operations. Only two of the remaining 10 patients had lasting clinical benefit from balloon dilatation. A 73 year old man, previously in the New York Heart Association's class III, had an unlimited effort tolerance after eight months; the area ofthe valve Gastrointestinal haemorrhage* 27 3 Heart failure 16 3 Heart failure 25 3 Not established 5 4 Sudden death (cardiac cause) 23 4 Cardiac arrest 20 4 Not established 8 6 Bronchial carcinoma 4 7 Heart failure 1 9
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Sudden death (cardiac cause) 7 13 Myocardial infarction* 29 and a suitable objective measurement (such as the distance walked in six minutes30) would be preferable for future studies.
The management of patients whose symptoms recur or worsen after balloon dilatation is difficult. Dilatation was repeated (without complication) in six patients, all of whom were in the New York Heart Association's class III or IV. The interval between procedures ranged from three to 12 (mean six) months. The mean area of the valve increased slightly but not significantly (from 0 61 (0-22) to 0-68 (0 23) cm2). Symptoms improved in only one patient.
Even though our patients were elderly and many had other disease, unrelieved aortic stenosis probably made an important contribution to the high mortality seen during follow up. The poor prognosis of symptomatic aortic stenosis is well recognised.3'-33 The area of the valve was less than 0 7 cm2 (that is, in the range defined as severe stenosis) in seven of 18 patients shortly after dilatation and in eight of 11 at follow up. Unless dilatation can consistently create an orifice with an area comparable with that of a prosthetic aortic valve (in most cases l 0-1l5 cm2 or more)3437 it is unlikely to confer the improved life expectancy that follows successful valve replacement.2 This cannot be achieved at present, and we therefore believe that valve dilatation should be used only for patients with severe symptoms in whom life expectancy is limited by other disease. Dilatation may have a place in the management of patients with aortic stenosis who present with cardiogenic shock or severe pulmonary oedema. The high mortality after emergency operations to replace aortic valves in the elderly3 might be reduced if left ventricular function could be improved before operation.
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